A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases

Brum, Wagner S.; Cullen, Nicholas; Janelidze, Shorena; Ashton, Nicholas J.; Zimmer, Eduardo R.; Therriault, Joseph; Benedet, Andréa Lessa; Rahmouni, Nesrine; Tissot, Cécile; Stevenson, Jenna; Servaes, Stijn; Triana‐Baltzer, Gallen; Kolb, Hartmuth C.; Palmqvist, Sebastian; Stomrud, Erik; Rosa‐Neto, Pedro; Blennow, Kaj; Hansson, Oskar

doi:10.1038/s43587-023-00471-5

articleNature AgingAug 31, 2023HYBRID OA

A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases

WSWagner S. Brum NCNicholas Cullen SJShorena Janelidze NJNicholas J. Ashton EREduardo R. Zimmer

Universidade Federal do Rio Grande do Sul · University of Gothenburg · +8 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

Cost-effective strategies for identifying amyloid-β (Aβ) positivity in patients with cognitive impairment are urgently needed with recent approvals of anti-Aβ immunotherapies for Alzheimer's disease (AD). Blood biomarkers can accurately detect AD pathology, but it is unclear whether their incorporation into a full diagnostic workflow can reduce the number of confirmatory cerebrospinal fluid (CSF) or positron emission tomography (PET) tests needed while accurately classifying patients. We evaluated a two-step workflow for determining Aβ-PET status in patients with mild cognitive impairment (MCI) from two independent memory clinic-based cohorts (n = 348). A blood-based model including plasma tau protein 217…

Citation impact

233

total citations

FWCI: 39.63
Percentile: 100%
References: 70

Citations per year

Authors

18

Topics & keywords

Topics

Keywords

Medicine
Workflow
Positron emission tomography
Internal medicine
Oncology
Cognitive impairment
Disease
Nuclear medicine

No related works found for this paper.